Clinuvel Pharmaceuticals (FRA:UR9) Net Income (Continuing Operations) : €18.62 Mil (TTM As of Dec. 2023)

View and export this data going back to 2004. Start your Free Trial

What is Clinuvel Pharmaceuticals Net Income (Continuing Operations)?

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Clinuvel Pharmaceuticals's Net Income (Continuing Operations) for the six months ended in Dec. 2023 was €6.71 Mil. Its Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Dec. 2023 was €18.62 Mil.

Clinuvel Pharmaceuticals Net Income (Continuing Operations) Historical Data

The historical data trend for Clinuvel Pharmaceuticals's Net Income (Continuing Operations) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clinuvel Pharmaceuticals Net Income (Continuing Operations) Chart

Clinuvel Pharmaceuticals Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Net Income (Continuing Operations)

Get a 7-Day Free Trial

11.15

10.20

15.69

13.88

18.96

Clinuvel Pharmaceuticals Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Net Income (Continuing Operations)	Get a 7-Day Free Trial															3.72	9.98	7.25	11.90	6.71

Clinuvel Pharmaceuticals Net Income (Continuing Operations) Calculation

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period.

Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €18.62 Mil.

Clinuvel Pharmaceuticals (FRA:UR9) Net Income (Continuing Operations) Explanation

Net Income (Continuing Operations) excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Clinuvel Pharmaceuticals Net Income (Continuing Operations) Related Terms

Thank you for viewing the detailed overview of Clinuvel Pharmaceuticals's Net Income (Continuing Operations) provided by GuruFocus.com. Please click on the following links to see related term pages.

Clinuvel Pharmaceuticals (FRA:UR9) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clinuvel Pharmaceuticals Ltd (FRA:UR9) » Definitions » Net Income (Continuing Operations)

Comparable Companies

Traded in Other Exchanges

CLVLY:USA CLVLF:USA UR9:Germany CUV:Australia

Address

535 Bourke Street, Level 11, Melbourne, VIC, AUS, 3000

Website

https://www.clinuvel.com

Clinuvel distributes a single-product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient's quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel's earnings stem from Europe and the U.S.

Clinuvel Pharmaceuticals (FRA:UR9) Headlines

No Headlines